Additionally, pharmacological inhibition of CLK1 has been investigated pre-clinically for the treatment of Duchenne muscular dystrophy (Sako et al., 2017) and Alzheimer’s disease (Jain et al., 2014; Hedou et al., 2016; Murar et al., 2017). This evidence concerns the gene CLK1 and early-onset autosomal dominant Alzheimer disease.